Abstract:The study aimed to evaluate the potential of piperidine-based 2H chromen-2-one derivatives against targeted enzymes, i.e., cholinesterase's and monoamine oxidase enzymes. The compounds were divided into three groups, i.e., 4a–m ((3,4-dimethyl-7-((1-methylpiperidin-4-yl)oxy)-2H-chromen-2-one derivatives), 5a–e (3,4-dimethyl-7-((1-methypipridin-3-yl)methoxy)-2H-chromen-2-one derivatives), and 7a–b (7-(3-(3,4-dihydroisoquinolin-2(1H)-yl)propoxy)-3,4-dimethyl-2H-chromen-2-one derivatives) with slight difference in the basic structure. The comprehensive computational investigations were conducted including density functional theories studies (DFTs), 2D-QSAR studies, molecular docking, and molecular dynamics simulations. The QSAR equation revealed that the activity of selected chromen-2-one-based piperidine derivatives is being affected by the six descriptors, i.e., Nitrogens Count, SdssCcount, SssOE-Index, T-2–2-7, ChiV6chain, and SssCH2E-Index. These descriptor values were further used for the preparation of chromen-2-one based piperidine derivatives. Based on this, 83 new derivatives were created from 7 selected parent compounds. The QSAR model predicted their IC 50 values, with compound 4 k and 4kk as the most potent multi-targeted derivative. Molecular docking results exhibited these compounds as the best inhibitors; however, 4kk exhibited greater activity than the parent compounds. The results were further validated by molecular dynamic simulation studies along with the suitable physicochemical properties. These results prove to be an essential guide for the further design and development of new piperidine based chromen-2-one derivatives having better activity against neurodegenerative disorder.

2,6-Disubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors

2,6-Disubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitors.

Small conformationally restricted piperidine N-arylsulfonamides as orally active γ-secretase inhibitors

Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer’s disease

Discovery of Clinical Candidate PF-06648671: A Potent γ-Secretase Modulator for the Treatment of Alzheimer's Disease

Discovery of SCH 900229, a Potent Presenilin 1 Selective γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease.

Discovery of 4-(Arylethynyl)piperidine Derivatives as Potent Nonsaccharide O-GlcNAcase Inhibitors for the Treatment of Alzheimer's Disease

Design, synthesis, and evaluation of 2-piperidone derivatives for the inhibition of β-amyloid aggregation and inflammation mediated neurotoxicity

Structure Activity Relationship Studies of Tricyclic Bispyran Sulfone Γ-Secretase Inhibitors

Novel Orally Active Morpholine N-arylsulfonamides Γ-Secretase Inhibitors with Low CYP 3A4 Liability

Modulation of gamma-secretase specificity using small molecule allosteric inhibitors.

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

An Integrated Computational Approaches for Designing of Potential Piperidine based Inhibitors of Alzheimer Disease by Targeting Cholinesterase and Monoamine Oxidases Isoenzymes

Cyclic Hydroxyamidines As Amide Isosteres: Discovery of Oxadiazolines and Oxadiazines As Potent and Highly Efficacious Γ-Secretase Modulators in Vivo.

Design, Synthesis and Biological Evaluation of 3-Piperazinecarboxylate Sarsasapogenin Derivatives As Potential Multifunctional Anti-Alzheimer Agents.

A Local Desymmetrization Approach to Piperidinyl Acetic Acid γ-Secretase Modulators

Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer’s disease

Structural basis of -secretase inhibition and modulation by small molecule drugs

Design, synthesis, and pharmacological evaluation of indole-piperidine amides as Blood−brain barrier permeable dual cholinesterase and β-secretase inhibitors

Spirocyclic Sulfamides As Β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer's Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies to Identify Centrally Efficacious Inhibitors.

Piperazine Sulfonamide BACE1 Inhibitors: Design, Synthesis, and in Vivo Characterization